Biomarkers of oxidative damage and inflammation in Alzheimers disease

Biomarkers in Medicine

Volumn 4, Issue 1, 2010, Pages 27-36

  Galasko, Douglas ^a   Montine, Thomas J ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Alzheimer's disease; Biomarker; Cytokines; F2 isoprostanes; Oxidative stress

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1BETA; INTERLEUKIN 8; ISOPROSTANE DERIVATIVE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE MIGRATION INHIBITION FACTOR; NUCLEIC ACID; PROTEIN; PROTEIN S100B; TUMOR NECROSIS FACTOR ALPHA;

ALZHEIMER DISEASE; ASTROCYTE; BLOOD; CELL ACTIVATION; CELL MEMBRANE; CEREBROSPINAL FLUID; CLINICAL RESEARCH; DEGENERATIVE DISEASE; HUMAN; INFLAMMATION; LIPID PEROXIDATION; MICROGLIA; NITROSYLATION; NONHUMAN; OXIDATIVE STRESS; PROTEIN PROCESSING; REVIEW; URINE;

ALZHEIMER DISEASE; BIOLOGICAL MARKERS; CYTOKINES; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; OXIDATIVE STRESS;

EID: 77951689435     PISSN: 17520363     EISSN: None     Source Type: Journal    
DOI: 10.2217/bmm.09.89     Document Type: Review

References (59)

1. Markesbery WR: Oxidative stress hypothesis in Alzheimer's disease. Free Radic. Biol. Med. 23, 134-147 (1997).
2. Perry G, Nunomura A, Hirai K et al.: Is oxidative damage the fundamental pathogenic mechanism of Alzheimer's and other neurodegenerative diseases? Free Radic. Biol. Med. 33, 1475-1479 (2002).
3. Golden TR, Hinerfeld DA, Melov S: Oxidative stress and aging: beyond correlation. Aging Cell 1, 117-123 (2002).
4. Keller JN, Schmitt FA, Scheff SW et al.: Evidence of increased oxidative damage in subjects with mild cognitive impairment. Neurology 64, 1152-1156 (2005).
5. Schwab C, McGeer PL: Infammatory aspects of Alzheimer disease and other neurodegenerative disorders. J. Alzheimers Dis. 13, 359-369 (2008).
6. Rozemuller AJ, van Gool WA, Eikelenboom P: The neuroinfammatory response in plaques and amyloid angiopathy in Alzheimer's disease: therapeutic implications. Curr. Drug Targets CNS Neurol. Disord. 4, 223-233 (2005).
7. Lucin KM, Wyss-Coray T: Immune activation in brain aging and neurodegeneration: too much or too little? Neuron 64, 110-122 (2009).
8. Bertram L, Tanzi RE: Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses. Nat. Rev. Neurosci. 9, 768-778 (2008).
9. Lambert JC, Heath S, Even G et al.: Genome-wide association study identifes variants at CLU and CR1 associated with Alzheimer's disease. Nat. Genet. 41, 1094-1099 (2009).
10. Harold D, Abraham R, Hollingworth P et al.: Genome-wide association study identifes variants at CLU and PICALM associated with Alzheimer's disease. Nat. Genet. 41, 1088-1093 (2009).
11. Kim J, Basak JM, Holtzman DM: The role of apolipoprotein E in Alzheimer's disease. Neuron 63, 287-303 (2009).
12. Kadiiska MB, Gladen BC, Baird DD et al.: Biomarkers of oxidative stress study II: are oxidation products of lipids, proteins, and DNA markers of CCl4 poisoning? Free Radic. Biol. Med. 38, 698-710 (2005).
13. 1-42 in cerebrospinal fuid and plasma. Amyloid 7, 245-258 (2000).
14. Abe T, Tohgi H, Isobe C, Murata T, Sato C: Remarkable increase in the concentration of 8-hydroxyguanosine in cerebrospinal fuid from patients with Alzheimer's disease. J. Neurosci. Res. 70, 447-450 (2002).
15. 2-isoprostanes as biomarkers of late-onset Alzheimer's disease. J. Mol. Neurosci. 33, 114-119 (2007).
16. Praticò D, Uryu K, Leight S, Trojanoswki JQ, Lee VM: Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J. Neurosci. 21, 4183-4187 (2001).
17. Yao Y, Zhukareva V, Sung S et al.: Enhanced brain levels of 8,12-iso-iPF2a-VI differentiate AD from frontotemporal dementia. Neurology 61, 475-478 (2003).
18. 2-isoprostane concentration in probable Alzheimer's disease. Neurology 52, 562-565 (1999).
19. Pratico D, Clark CM, Lee VMY, Trojanowski JQ, Rokach J, Fitzgerald G: Increased 8,12-iso-iPF2a-IV in Alzheimer's disease: correlation of a noninvasive index of lipid peroxidation with disease severity. Ann. Neurol. 48, 809-812 (2000).
20. 2-isoprostane concentrations in patients with Alzheimer's disease, other dementias, and age-matched controls. Arch. Pathol. Lab. Med. 125, 510-512 (2001).
21. Pratico D, Clark CM, Liun F, Rokach J, Lee VY, Trojanowski JQ: Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease. Arch. Neurol. 59, 972-976 (2002).
22. de Leon MJ, Mosconi L, Li J et al.: Longitudinal CSF isoprostane and MRI atrophy in the progression to AD. J. Neurol. 254, 1666-1675 (2007).
23. Ringman JM, Younkin SG, Pratico D et al.: Biochemical markers in persons with preclinical familial Alzheimer disease. Neurology 71, 85-92 (2008).
24. 4-neuroprostanes are not increased in Alzheimer's disease, Ann. Neurol. 52, 175-179 (2002).
25. Irizarry MC, Yao Y, Hyman BT, Growdon JH, Praticò D: Plasma F2A isoprostane levels in Alzheimer's and Parkinson's disease. Neurodegener. Dis. 4, 403-405 (2007).
26. 2-isoprostanes in Alzheimer's disease. J. Alzheimers Dis. 6, 93-97 (2004).
27. Pirttila T, Mehta PD, Frey H, Wisniewski HM: a1-antichymotrypsin and IL-1b are not increased in CSF or serum in Alzheimer's disease. Neurobiol. Aging 15, 313-317 (1994).
28. Teunissen CE, de Vente J, Steinbusch HW, De Bruijn C: Biochemical markers related to Alzheimer's dementia in serum and cerebrospinal fuid. Neurobiol. Aging 23, 485-508 (2002).
29. DeKosky ST, Ikonomovic MD, Wang X et al.: Plasma and cerebrospinal fuida1-antichymotrypsin levels in Alzheimer's disease: correlation with cognitive impairment. Ann. Neurol. 53, 81-90 (2003).
30. Gonçalves CA, Leite MC, Nardin P: Biological and methodological features of the measurement of s100B, a putative marker of brain injury. Clin. Biochem. 41, 755-763 (2008).
31. Peskind ER, Griffn WS, Akama KT, Raskind MA, Van Eldik LJ: Cerebrospinal fuid s100B is elevated in the earlier stages of Alzheimer's disease. Neurochem. Int. 39, 409-413 (2001).
32. Petzold A, Jenkins R, Watt HC et al.: Cerebrospinal fuid s100B correlates with brain atrophy in Alzheimer's disease. Neurosci. Lett. 336, 167-170 (2003).
33. Rosengren LE, Wikkelsø C, Hagberg L: A sensitive ELISA for glial fbrillary acidic protein: application in CSF of adults. Neurosci. Methods 51, 197-204 (1994).
34. Jesse S, Steinacker P, Cepek L et al.: Glial fbrillary acidic protein and protein S-100B: different concentration pattern of glial proteins in cerebrospinal fuid of patients with Alzheimer's Disease and Creutzfeldt-Jakob disease. J. Alzheimers Dis. 5(4 Suppl. 1), 505-506 (2009).
35. Tarkowski E, Blennow K, Wallin A, Tarkowski A: Intracerebral production of tumor necrosis factor-a, a local neuroprotective agent, in Alzheimer disease and vascular dementia. J. Clin. Immunol. 19, 223-230 (1999).
36. Tarkowski E, Andreasen N, Tarkowski A, Blennow K: Intrathecal infammation precedes development of Alzheimer's disease. J. Neurol. Neurosurg. Psychiatr. 74, 1200-1205 (2003).
37. Garlind A, Brauner A, Höjeberg B, Basun H, Schultzberg M: Soluble interleukin-1 receptor type II levels are elevated in cerebrospinal fuid in Alzheimer's disease patients. Brain Res. 826, 112-116 (1999).
38. Blasko I, Lederer W, Oberbauer H et al.: Measurement of thirteen biological markers in CSF of patients with Alzheimer's disease and other dementias. Dement. Geriatr. Cogn. Disord. 21, 9-15 (2006).
39. Lindberg C, Chromek M, Ahrengart L, Brauner A, Schultzberg M, Garlind A: Soluble interleukin-1 receptor type II, IL-18 and caspase-1 in mild cognitive impairment and severe Alzheimer's disease. Neurochem. Int. 46, 551-557 (2005).
40. Popp J, Bacher M, Kölsch H et al.: Macrophage migration inhibitory factor in mild cognitive impairment and Alzheimer's disease. J. Psychiatr. Res. 43, 749-753 (2009).
41. van Exel E, Eikelenboom P, Comijs H et al.: Vascular factors and markers of infammation in offspring with a parental history of late-onset Alzheimer disease. Arch. Gen. Psychiatry 66, 1263-1270 (2009).
42. Sun YX, Minthon L, Wallmark A, Warkentin S, Blennow K, Janciauskiene S: Infammatory markers in matched plasma and cerebrospinal fuid from patients with Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 16, 136-144 (2003).
43. Galimberti D, Schoonenboom N, Scheltens P et al.: Intrathecal chemokine synthesis in mild cognitive impairment and Alzheimer disease. Arch. Neurol. 63, 538-543 (2006).
44. Choi C, Jeong JH, Jang JS et al.: Multiplex ana lysis of cytokines in the serum and cerebrospinal fuid of patients with Alzheimer's disease by color-coded bead technology. J. Clin. Neurol. 4, 84-88 (2008).
45. Nilselid AM, Davidsson P, Nägga K, Andreasen N, Fredman P, Blennow K: Clusterin in cerebrospinal fuid: ana lysis of carbohydrates and quantifcation of native and glycosylated forms. Neurochem. Int. 48, 718-728 (2006).
46. Freund-Levi Y, Hjorth E, Lindberg C et al.: Effects of omega-3 fatty acids on infammatory markers in cerebrospinal fuid and plasma in Alzheimer's disease: the OmegAD study. Dement. Geriatr. Cogn. Disord. 27, 481-490 (2009).
47. Engelhart MJ, Geerlings MI, Meijer J et al.: Infammatory proteins in plasma and the risk of dementia: the Rotterdam study. Arch. Neurol. 61, 668-672 (2004).
48. Tan ZS, Beiser AS, Vasan RS et al.: Infammatory markers and the risk of Alzheimer disease: the Framingham Study. Neurology 68, 1902-1908 (2007).
49. Roberts RO, Geda YE, Knopman DS et al.: Association of C-reactive protein with mild cognitive impairment. Alzheimers Dement. 5, 398-405 (2009).
50. Holmes C, Cunningham C, Zotova E et al.: Systemic infammation and disease progression in Alzheimer disease. Neurology 73, 768-774 (2009).
51. Ray S, Britschgi M, Herbert C et al.: Classifcation and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat. Med. 13, 1359-1362 (2007).
52. Blum-Degen D, Müller T, Kuhn W, Gerlach M, Przuntek H, Riederer P: Interleukin-1b and interleukin-6 are elevated in the cerebrospinal fuid of Alzheimer's and de novo Parkinson's disease patients. Neurosci. Lett. 202, 17-20 (1995).
53. Galimberti D, Venturelli E, Fenoglio C et al.: Intrathecal levels of IL-6, IL-11 and LIF in Alzheimer's disease and frontotemporal lobar degeneration. J. Neurol. 255, 539-544 (2008).
54. Gómez-Tortosa E, Gonzalo I, Fanjul S et al.: Cerebrospinal fuid markers in dementia with lewy bodies compared with Alzheimer disease. Arch. Neurol. 60, 1218-1222 (2003). (Pubitemid 37099626)
55. Hampel H, Schoen D, Schwarz MJ et al.: Interleukin-6 is not altered in cerebrospinal fuid of frst-degree relatives and patients with Alzheimer's disease. Neurosci. Lett. 228, 143-146 (1997).
56. Tarkowski E, Wallin A, Regland B, Blennow K, Tarkowski A: Local and systemic GM-CSF increase in Alzheimer's disease and vascular dementia. Acta Neurol. Scand. 103, 166-174 (2001).
57. Rota E, Bellone G, Rocca P, Bergamasco B, Emanuelli G, Ferrero P: Increased intrathecal TGF-b1, but not IL-12, IFN-γ and IL-10 levels in Alzheimer's disease patients. Neurol. Sci. 27, 33-39 (2006).
58. Zetterberg H, Andreasen N, Blennow K: Increased cerebrospinal fuid levels of transforming growth factor-b1 in Alzheimer's disease. Neurosci. Lett. 367, 194-196 (2004).
59. Tarkowski E, Issa R, Sjögren M et al.: Increased intrathecal levels of the angiogenic factors VEGF and TGF-b in Alzheimer's disease and vascular dementia. Neurobiol. Aging 23, 237-243 (2002).